Absci Corp
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Absci Corp (ABSI) | 1.30B | -9.51 | 5.93 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 121.5% below Morningstar's fair value estimate.
Fair value
Absci Corp receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 49% discount to our quantitative fair value estimate of $16.64 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The firm's liquidity strengthens our fair value estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days lies in the top 20% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.
Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio, a core component of valuation, sits in the top 1% compared with global peers. This overstates the long-term cash flow growth potential of the organization. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
Absci Corp discussion 0 comments